Article
Final Analysis of Outcomes and RAS/BRAF Status in a Randomized Phase 3 Study of Panitumumab and Best Supportive Care in Chemorefractory Wild Type KRAS Metastatic Colorectal Cancer.
Clinical colorectal cancer - 1 Sept 2018
Kim Tae Won, Elme Anneli, Park Joon Oh, Udrea Anghel Adrian, Kim Sun Young, Ahn Joong Bae, Valencia Ricardo Villalobos, Krishnan Srinivasan, Manojlovic Nebojsa, Guan Xuesong, Lofton-Day Catherine, Jung A Scott, Vrdoljak Eduard
Abstract excerpt
INTRODUCTION: Tumor rat sarcoma gene (RAS) status is a negative predictive biomarker for anti-epidermal growth factor receptor (EGFR) therapy in metastatic colorectal cancer (mCRC). We analyzed outcomes according to RAS and v-Raf murine sarcoma viral oncogene homolog B (BRAF) mutational status, and evaluated early tumor shrinkage (ETS) and depth of response (DpR) for patients with wild type RAS. PATIENTS AND...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.